Financial & competing interests disclosure
M Sarazin has received speaker honoraria from Eisai, Pfizer, Lundbeck, Janssen and Novartis; she belongs to a scientific advisory board for Eisai and serves as an Associate Editor for La Lettre du Neurologue. B Dubois has consulted or served on advisory boards for Bristol-Myers Squibb, Roche, Elan, Eli Lilly, Eisai and Janssen. His institution has received grants from Novartis and Sanofi-Aventis. L Cruz de Souza has received speakers honoraria from Lundbeck. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
No writing assistance was utilized in the production of this manuscript.